VantAI is the world's leading engine for the computational design and optimization of targeted protein degraders.
Algorithmically designed therapies, reverse engineered from target and disease biology.
Rapid and accurate modality agnostic target prediction for existing assets and AI-powered novel MOA understanding down to the atomic level.
Systematically link targets with disease, down to a molecular pathway level.
Task-specific models for ADMET properties that leverage the power of embeddings and transfer learning to deal with low data realities.
Algorithmically design drugs, reverse engineered from target and disease biology.
Rapid and accurate modality agnostic target prediction for existing assets and AI-powered novel MOA understanding down to the atomic level.
Systematically link targets with disease, down to a molecular pathway level.
Task-specific models for ADMET properties that leverage the power of embeddings and transfer learning to deal with low data realities.
ML-driven methodology leverages information about known protein-protein interactions to rapidly build new degraders that can effectively stabilize target-E3 interfaces.
Unique model predicts degradation based on millions of carefully curated protein stability data points.
The world's leading map of the ubiquitin proteasome system connects E3s to specific degron motifs.
Novel assay workflow for rapidly confirming degradation activity of hundreds of compounds against dozens of targets in vitro.
We power the design and development of novel therapies and find new uses for existing ones.
We partner with CROs and organ-on-a-chip companies to offer sponsors a full suite of integrated in silico and wet-lab solutions.
VantAI’s platform supports cutting-edge research at leading academic labs and non-profit institutions.
VantAI’s cutting-edge tools help the world’s sharpest biotech investors identify and assess opportunities.
ML-driven methodology leverages information about known protein-protein interactions to rapidly build new degraders that can effectively stabilize target-E3 interfaces.
We are obsessed with the potential of AI, but recognize the complexity of biology. It is our mission to see the two intersect in a way that brings maximum impact on disease.
By strategic design, VantAI does not pursue its own clinical pipeline, instead it is our vision to be the AI partner that furthers the potential of hundreds of pharmaceuticals and biotechs around the world.
Novel assay workflow for rapidly confirming degradation activity of hundreds of compounds against dozens of targets in vitro.
We are obsessed with the potential of AI, but recognize the complexity of biology. It is our mission to see the two intersect in a way that brings maximum impact on disease.
By strategic design, VantAI does not pursue its own clinical pipeline, instead it is our vision to be the AI partner that furthers the potential of hundreds of pharmaceuticals and biotechs around the world.
We’re a community of scientists, engineers, and developers that shares an academic spirit at the speed of a start-up.
MEET OUR TEAMIf you are looking for a role at the bleeding edge of artificial intelligence, where your impact is immediate and meaningful, this is it.
Apply your skills to help us tackle some of the most complex and meaningful scientific challenges on the planet.
Get in touch with us for any questions or comments regarding our abilities, career opportunities, or potential collaborations. We’d love to hear from you.
33 Irving Place
Floor 10
New York, NY
United States